Previous studies showed that the leukotrienes pathway is increased in human tauopathy and that its manipulation may modulate the onset and development of the pathological phenotype of tau transgenic mice. However, whether interfering with leukotrienes biosynthesis is beneficial after the behavioral deficits and the neuropathology have fully developed in these mice is not known. To test this hypothesis, aged tau transgenic mice were randomized to receive zileuton, a specific leukotriene biosynthesis inhibitor, or vehicle starting at 12 months of age for 16 weeks and then assessed in their functional and pathological phenotype. Compared with baseline, we observed that untreated tau mice had a worsening of their memory and spatial learning. By contrast, tau mice treated with zileuton had a reversal of these deficits and behaved in an undistinguishable manner from wild-type mice. Leukotriene-inhibited tau mice had an amelioration of synaptic integrity, lower levels of neuroinflammation, and a significant reduction in tau phosphorylation and pathology, which was secondary to an involvement of the cdk5 kinase pathway. Taken together, our findings represent the first demonstration that the leukotriene biosynthesis is functionally involved at the later stages of the tau pathological phenotype and represents an ideal target with viable therapeutic potential for treating human tauopathies.
This is a preview of subscription content, log in to check access.
PFG and DP designed the study; PFG and JC performed the experiments; PFG and DP analyzed the data and drafted the manuscript. All authors have discussed the results and seen the final version of the paper before submission.
Domenico Praticò is the Scott Richards North Star Foundation Chair of Alzheimer’s research. This study was supported in part by grants from The Wanda Simone Endowment for Neuroscience and the Scott Richards North Star Charitable Foundation.
Compliance with Ethical Standards
Conflict of Interest
The authors have no conflicting financial interest to disclose.
Yerbury JJ, Ooi L, Dillin A, Saunders DN, Hatters DM, Berat PM, Cashman NR, Wilson MR et al (2016) Walking the tightrope: proteostasis and neurodegenerative diseases. J Neurochem 137:489–505CrossRefPubMedGoogle Scholar
Ishizawa K, Dickson DW (2001) Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 60:647–657CrossRefPubMedGoogle Scholar
Laurent C, Dorothee G, Hunot S, Martin E, Monnet Y, Duchamp M, Dong Y, Légeron FP et al (2007) Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain 140:184–200CrossRefGoogle Scholar
Giannopoulos PF, Chu J, Sperow N, Li JG, Yu WH, Kirby LG, Abood M, Praticò D (2015) Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol Psychiatry 78:693–701CrossRefPubMedPubMedCentralGoogle Scholar
Joshi Y, Praticò D (2015) The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer’s disease pathogenesis. Front Cell Neurosci 8(436):1–8Google Scholar
Vagnozzi AN, Giannopoulos PF, Praticò D (2017) The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. Transl. Psychiatry 7(12):1288Google Scholar
Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582–590CrossRefPubMedGoogle Scholar
Chu J, Li JG, Praticò D (2013) Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer’s disease with plaques and tangles. PLoS One 8:e70991CrossRefPubMedPubMedCentralGoogle Scholar
Di Meco A, Joshi YB, Praticò D (2014) Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer’s disease with plaques and tangles. Neurobiol Aging 35(8):1813–1820CrossRefPubMedGoogle Scholar
Giannopoulos PF, Chu J, Joshi YB, Sperow M, Li JG, Kirby LG, Praticò D (2013) Five-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer’s disease. Biol Psychiatry 74:348–356CrossRefPubMedPubMedCentralGoogle Scholar
Chiti F, Dobson CM (2017) Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 86:27–68CrossRefPubMedGoogle Scholar
Li C, Götz J (2017) Tau-based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discov 16(12):863–883CrossRefPubMedGoogle Scholar
Braczynski AK, Schulz JB, Bach JP (2017) Vaccination strategies in tauopathies and synucleinopathies. J Neurochem 143(5):467–488CrossRefPubMedGoogle Scholar
Wahl D, Coogan SC, Solon-Biet SM, de Cabo R, Haran JB, Raubenheimer D, Cogger VC, Mattson MP et al (2017) Cognitive and behavioral evaluation of nutritional interventions in rodent models of brain aging and dementia. Clin Interv Aging 12:1419–1428CrossRefPubMedPubMedCentralGoogle Scholar
Stewart S, Cacucci F, Lever C (2011) Which memory task for my mouse? A systematic review of spatial memory performance in the Tg2576 Alzheimer’s mouse model. J Alzheimers Dis 26(1):105–126CrossRefPubMedGoogle Scholar
Steinhilber D, Hofmann B (2014) Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin Pharmacol Toxicol 114(1):70–77CrossRefPubMedGoogle Scholar
Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K (2013) Abnormal hyperphosphorylation of tau: sites, regulation and molecular mechanism of neurofibrillary degeneration. J Alz Dis 33(suppl.1):S123–S139Google Scholar
Alldred MJ, Duff KE, Ginsberg SD (2012) Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol Dis 45:751–762CrossRefPubMedGoogle Scholar
Giannopoulos PF, Joshi YB, Praticò D (2014) Novel lipid signaling pathways in Alzheimer disease pathogenesis. Biochem Pharmacol 88(4):560–564CrossRefPubMedGoogle Scholar
Chen MH, Li CT, Tsai CF, Lin WC, Chang WH, Chen TJ, Pan TJ, Su TL et al (2014) Risk of dementia among patients with asthma: a nationwide longitudinal study. J Am Med Dir Assoc 15(10):763–767CrossRefPubMedGoogle Scholar
Peng YH, Wu BR, Liao WC, Muo WC, Hsia TC, Kao CH (2015) Adult asthma increases dementia risk: a nationwide cohort study. J Epidemiol Comm Health 69(2):123–128CrossRefGoogle Scholar